Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors

Pharmacopsychiatry

Volumn 34, Issue 4, 2001, Pages 119-127

  Zullino, D ^a   Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; LITHIUM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTIMANIC AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; SEROTONIN UPTAKE INHIBITORS;

EID: 0034923047     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15873     Document Type: Review

References (97)

1. Lithium in der behandlung der akuten depression
2. Practice guideline for major depressive disorder in adults
3. SSRIS versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability
4. Triiodthyronine augmentation in the treatment of refractory depression
5. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients
6. Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly
7. The combined use of lithium and SSRIs
8. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine
9. Treatment of refractory depression with high dose thyroxine
10. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies
11. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression
12. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation
13. Care of depression in the elderly: Comparative pharmacokinetics of SSRIs
14. The use of pindolol to potentiate antidepressant medication
15. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy
16. Pharmacokinetic interactions between lithium and fluoxetine after single and repeated fluoxetine administration in young healthy volunteers
17. Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments
18. The treatment of refractory depression using paroxetine with lithium augmentation
19. Lithium treatment and the geriatric population
20. Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders
21. Lithium carbonate additionin tricyclic antidepressant-resistant unipolar depression
22. Lithium addition in treatment-resistant depression
23. Efficacy of fluvoxamine in treatment-refractory depression
24. The use of anticonvulsants to augment antidepressant medication
25. A rational approach to the non-responding depressed patient
26. Lithium augmentation in sertraline-resistant depression: A preliminary dose-response study
27. Dexamethasone augmentation in treatment-resistant depression
28. Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients
29. Systematic review and guide to selection of selective serotonin reuptake inhibitors
30. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment
31. Fluvoxamine and lithium: An unusual interaction
32. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine
33. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study
34. Clinical relevance of drug interactions with lithium
35. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression
36. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression
37. Mood stabilizer combinations: A review of safety and efficacy
38. Is the EEG helpful in diagnosing and monitoring lithium intoxication? A case report and review of the literature
39. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: Methods and first results for tricyclic antidepressants and SSRI
40. The clinical meaning of refractory depression: A review for the clinician
41. Mania resulting from lithium-fluoxetine combination
42. Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression
43. Tolerability of combined treatment with lithium and fluoxetine: 14 Cases treated under open conditions
44. Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions
45. Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: A review of the current evidence
46. Lithium augmentation of antidepressants in treatment-refractory depression
47. Serotonin syndrome and drug combinations: Focus on MAOI and RIMA
48. The combination of fluoxetine and lithium in clinical practice
49. Refractory depression: Treatment strategies, with particular reference to the thyroid axis
50. The use of thyroid supplements to augment antidepressant medication
51. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it
52. Refractory depression: A review with particular reference to the use of lithium augmentation
53. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine
54. Switching drug class after initial SSRI failure
55. Serotonin syndrome during clomipramine and lithium treatment
56. Long-term treatment of depression
57. Neurobiology of lithium: An update
58. Pharmacological and biochemical aspects of therapy-resistant depression
59. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy
60. A case of serotonin syndrome caused by venlafaxine and lithium
61. Efficacy in long-term treatment of depression
62. Pindolol augmentation of treatment-resistant depressed patients
63. Serotonin syndrome produced by a combination of fluoxetine and lithium
64. Lithium or desipramine augmentation of fluoxetine treatment
65. Augmentation strategies with serotonergic-noradrenergic combinations
66. Treatment-resistant depression: Definition and treatment approaches
67. A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium
68. Possible toxicity of combined fluoxetine and lithium
69. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression
70. Addition of lithium to chronic antidepressant treatment potentiates presynaptic serotonergic function without changes in serotonergic receptors in the rat cerebral cortex
71. Serotonin syndrome induced by fluvoxamine-lithium interaction
72. Possible synergism between fluoxetine and lithium in refractory depression
73. Variability of response to lithium augmentation in refractory depression
74. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression
75. SSRI supplementation of antimanic medication in dysphoric mania
76. The use of lithium to augment antidepressant medication
77. Strategies and tactics in the treatment of chronic depression
78. Absence seizures induced by lithium: Possible interaction with fluoxetine
79. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate
80. Kombinationstherapien bei therapieresistenz auf antidepressiva - Eine übersicht
81. Has the time come to abandon prophylactic lithium treatment? A review for clinicians
82. Treatment of depression resistant to tricyclic antidepressants, related drugs or MAO-inhibits by lithium addition: Review of the literature
83. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: Results of a placebo-controlled double-blind study
84. Combination tratement with noradrenaline and serotonin reuptake inhibitors in resistant depression
85. A possible case of lithium intoxication mimicking Creutzfeld-Jakob syndrome
86. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression
87. Serotonin syndrome after lithium add-on medication to paroxetine
88. Practical guidelines for combination drug therapy of treatment-resistant depression
89. Should thyroid augmentation precede lithium augmentation - Pilot study
90. Buspirone augmentation of a selective serotonin reuptake inhibitor: Efficacy in two depressed patients with comorbid anxiety and type I alcohol dependence
91. The serotonin syndrome
92. Augmentation of antidepressant medication
93. Rapid synergistic effects of lithium and antidepressants
94. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline
95. Treating antidepressant nonresponders with augmentation strategies: An overview
96. 1A receptor mediated 5-HT behavioral syndrome induced by 8-OH-DPAT in rats via catecholaminergic systems
97. Citalopram-lithium combination treatment of elderly depressed patients: A pilot study